> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Teva Recalls 1 Lot of IDArubicin Injection
- URL: https://www.fdaweb.com/teva-recalls-1-lot-of-idarubicin-injection/
- Published: 2022-03-30T12:00:00.000Z
- Updated: 2026-09-14T17:38:46.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151484

FDA says Teva has recalled one lot of IDArubicin hydrochloride injection 5 mg/5 mL vial based on an internal inspection that found particulate matter in one vial of the product identified as silica and iron oxide. An agency [notice](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/teva-issues-voluntary-nationwide-recall-one-lot-idarubicin-hydrochloride-injection-usp-5-mg5-ml-due?ref=fdaweb.com) says no other vials have been observed to contain the defect and to date Teva has not received any product quality complaints or adverse event reports for the recalled lot.

The notice says IDArubicin injection is indicated in combination with other approved anti-leukemic drugs to treat acute myeloid leukemia in adults.